Ataciguat (HMR1766)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aortic Valve Stenosis
Conditions
Aortic Valve Stenosis
Trial Timeline
Jun 1, 2015 → Dec 1, 2019
NCT ID
NCT02481258About Ataciguat (HMR1766)
Ataciguat (HMR1766) is a phase 2 stage product being developed by Sanofi for Aortic Valve Stenosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02481258. Target conditions include Aortic Valve Stenosis.
What happened to similar drugs?
6 of 14 similar drugs in Aortic Valve Stenosis were approved
Approved (6) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02481258 | Phase 2 | Completed |
Competing Products
20 competing products in Aortic Valve Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 26 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 36 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 43 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 35 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 40 |
| candesartan + placebo | AstraZeneca | Phase 3 | 36 |
| Sugammadex | Merck | Approved | 43 |
| bisoprolol + placebo | Merck | Approved | 35 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 42 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 42 |
| fluvastatin | Novartis | Phase 2 | 31 |
| ACZ885 + Placebo | Novartis | Phase 2 | 27 |
| Evolocumab + Placebo | Amgen | Phase 1 | 36 |
| atorvastatin (Lipitor) | Pfizer | Approved | 35 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 40 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 29 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 35 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 29 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 37 |
| Desflurane | Baxter | Approved | 36 |